We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





World’s First Online Image-Based COVID-19 Diagnosis Improvement Tool Launched

By LabMedica International staff writers
Posted on 03 Apr 2020
Print article
Image: DetectED-X platform (Photo courtesy of DetectED-X)
Image: DetectED-X platform (Photo courtesy of DetectED-X)
DetectED-X (Sydney, Australia), a University of Sydney spinoff comprising radiation and imaging experts, has launched the world’s only online image-based COVID-19 diagnosis improvement tool for healthcare workers. The start-up has directed its breast cancer diagnosis tool at the coronavirus, drawing on pandemic cases globally with support from healthcare and industry leaders to ramp up COVID-19 detection. DetectED-X’s CovED platform, which can be accessed anywhere with an internet connection, is being provided for free and is supported by healthcare experts and leading corporations globally.

DetectED-X’s CovED follows on from the highly successful BreastScreen Reader Assessment Strategy (BREAST) platform, created in 2010 at the University of Sydney, which has been used internationally including in the US and Europe. The cloud-based life-saving technology can help doctors and radiologists diagnose cases faster and more accurately. Computed tomography (CT) lung scans, which produce cross-sectional images using X-rays and computers, are typically used after swabs are taken, to identify the extent and location of the disease; the CT scans produce images within minutes and are also able to diagnose COVID-19 in the very early stages that escape detection with nucleic acid tests.

DetectED-X’s approach, which includes algorithms to improve radiologist skills and identifying where errors were made on images in the online training sessions, has been shown to improve results significantly. Through CovED, individual clinicians can assess their performance on images on screen, and receive immediate feedback, including performance scores used in the industry. The image files personalized for each clinician are instantly returned showing any errors in their virtual diagnosis and the difficulty level is increased over time. As COVID-19 testing ramps up, the platform could facilitate rapid training where required – with modules able to be completed in as little as an hour – upskilling staff unfamiliar with lung radiology to prepare standardized reports for expert review.

“Our platform does not replace expert medical and radiologic training but CovED provides an effective way to recognize rapidly the appearances of COVID-19, which could be critical in a situation of too many patients and not enough expert radiologists, with the modules taking just 1-2 hours to complete,” said CEO Professor Patrick Brennan, medical radiation scientist and educator from the University of Sydney School of Health Sciences, Faculty of Medicine and Health. “This will be immediately crucial in developing countries, where numbers of radiologists are often insufficient – our tests will help people not only diagnose COVID-19 but also identify potentially life-threatening cases wherever they are.”

Related Links:
DetectED-X

New
Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TETANUS Test
TETANUS VIRCLIA IgG MONOTEST
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.